Martin Christopher Nathan 4
4 · Oruka Therapeutics, Inc. · Filed Dec 11, 2025
Insider Transaction Report
Form 4
Martin Christopher Nathan
Director
Transactions
- Award
Stock Option (right to buy)
2025-12-11+35,000→ 35,000 totalExercise: $30.21Exp: 2035-12-10→ Common Stock (35,000 underlying)
Footnotes (1)
- [F1]The option vests as to 1/36 of the underlying shares monthly from December 11, 2025.